Femasys Pipeline
Products & Candidates
Femasys has developed a suite of products and product candidates that address several large global market segments in which there has been little advancement for many years.
Research
Pre-Clinical
PMA Clinical Studies
Stage I
(Safety)
Stage II
(Validation)
Stage III
(Pivotal)
US Approval
CE Mark
FemBloc®
Permanent Birth Control
FemChec®
Occlusion Confirmation
PMA Clinical Studies CE Mark US Approval Stage III
(Pivotal)
Stage II
(Validation)
Stage I
(Safety)
Pre-Clincal Research
FemBloc® Permanent Birth Control
FemChec® Occlusion Confirmation

Research
Pre-Clinical
De Novo Clinical Study
US Approval
CE Mark
FemaSeed
Localized Directional Insemination
FemVue®
Infertility Diagnosis
CE Mark US Approval De Novo
Clinical
Trial
Pre-Clincal Research
FemaSeed Localized Directed Insemination
FemVue® Infertility Diagnosis

N/A

Research
Pre-Clinical
Clinical Study
US Approval
CE Mark
FemCerv®
Endocervical Tissue Sampler
CE Mark US Approval
Clinical
Trial
Pre-Clincal Research
FemCerv® Endocervical Tissue
Sampler

N/A

Femasys is advancing two lead product candidate systems targeting permanent birth control and artificial insemination for infertility.
Features
  • In-office procedure (Non-surgical)
  • Utilizes temporary degradable biopolymer (No permanent implant)
  • Minimally invasive intrauterine dual directional delivery
  • Closes fallopian tubes with patient's own scar tissue (Potential to be safest most natural approach)
  • Quicker to perform and to return to normal activities than surgery
  • Confirmation of treatment success is achieved with FemChec*

* Product candidate that creates saline-air contrast for the same physician to confirm occlusion with ultrasound, avoiding radiology-based exam.

FemBloc Treatment
Additional Information
Clinical Trial Information | www.clinicaltrials.gov
FemBloc Recruitment Website | www.fembloc.com
Features
  • In-office procedure (Non-surgical)
  • Minimally invasive intrauterine single directional delivery
  • Allows localized directed delivery of sperm to selected fallopian tube (where conception occurs)
  • Less costly and less invasive than assisted reproduction
  • Confirmation of fallopian tube patency (open) is required before treatment and can be achieved with FemVue*
FemaSeed Treatment FemaSeed Treatment
*FemVue® Saline-Air Device Commercially Available in U.S., Europe, Canada, Japan, and Other Countries Healthcare Professional Website | hcp.femvue.com On-line Training and New Customer Support | www.femvuetraining.com Patient Website | www.femvue.com Features Practice Locator